Clinical Trial Update: Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the safety and efficacy of LEO 43204 given once daily for two consecutive days on actinic keratosis; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LEO 43204

Snippet

Sponsor: LEO Pharma | Conditions: Actinic Keratosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-18